24 completed, 6 terminated, 5 recruiting, 1 not yet recruiting. 16 Phase 3, 10 Phase 2, 5 Phase 4, 3 Phase 1, 1 Early Phase 1.
Follow Aztreonam: new trials by email Literature Review of Aztreonam trials Research Report on Aztreonam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aztreonam-Avibactam in Immunocompromised Hosts Aztreonam-Avibactam, Ceftazidime-Avibactam Plus Aztreonam - Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection | Recruiting | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | 814 | 2026-10-14 | 2026-10-22 | |
| Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation Ceftazidime - Avibactam ( CAZ-AVI), Meropenem-Vaborbactam, Imipenem+Relebactam - Liver Transplant, Carbapenem-resistant Enterobacterales | Phase 3 | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 168 | 2026-10-01 | 2026-08-12 |
| Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB ceftazidime-avibactam combined with aztreonam - Ceftazidime-avibactam, Aztreonam | Phase 4 | Recruiting | Jing Zhou | 144 | 2026-03-31 | 2026-03-17 |
| Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. Carbapenems, Anti-Gram-positive agent, Antifungal agent - Febrile Neutropenia | Recruiting | Shanxi Bethune Hospital | 20 | 2025-09-22 | 2025-10-02 | |
| Optimising TREATment for Severe Gram-Negative Bacterial Infections Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem - Bloodstream Infection, Ventilator Associated Bacterial Pneumonia | Phase 4 | Recruiting | National University of Singapore | 600 | 2025-04-21 | 2025-06-04 |
| Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections ATM-AVI, BAT - Gram-negative Bacterial Infections | Phase 2 | Recruiting | Pfizer | 48 | 2023-04-18 | 2026-07-01 |
| Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies CAZ/AVI plus Aztreonam, Conventional treatment - Carbapenem-Resistant Enterobacteriaceae Infection | Not applicable | Unknown | Qianfoshan Hospital | 427 | 2023-01-06 | 2023-05-09 |
| Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis Meropenem 1000 mg, Aztreonam 2000 mg, automated peritoneal dialysis with following long time dwell - Peritoneal Dialysis Associated Peritonitis, Peritoneal Dialysis (PD) | Phase 2 / Phase 3 | Completed | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology | 12 | 2021-08-31 | 2025-08-11 |
| Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis Aztreonam lysine, Placebo - Bronchiectasis Adult | Phase 4 | Terminated | University of Dundee | 34 | 2019-10-19 | 2026-01-12 |
| A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam AZACTAM, Ceftazidime-Avibactam - Bacterial Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2019-07-09 | 2022-06-07 |
| Aztreonam for Pharyngeal Gonorrhea Aztreonam - Gonorrhea of Pharynx, Gonorrhea | Phase 2 / Phase 3 | Completed | University of Washington | 32 | 2019-04-05 | 2022-01-18 |
| Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria AZLI, Placebo - Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis | Phase 3 | Terminated | Gilead Sciences | 149 | 2017-11-28 | 2022-06-14 |
| Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 SPR741, Ceftazidime, Piperacillin/tazobactam - Healthy Volunteers | Phase 1 | Completed | Spero Therapeutics | 27 | 2017-11-10 | 2018-01-05 |
| Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis Aztreonam, Standard Care - Cystic Fibrosis, Infection | Phase 4 | Completed | Liverpool Heart and Chest Hospital NHS Foundation Trust | 16 | 2017-01-01 | 2019-10-07 |
| Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease Oral Aztreonam, Nasal Aztreonam, Nasal Placebo - Cystic Fibrosis | Phase 2 | Terminated | Virginia Commonwealth University | 5 | 2017-01-01 | 2021-01-28 |
| Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae Antipseudomonal beta-lactam antibiotic, De-escalation(short-spectrum antibiotic) - Enterobacteriaceae Infections | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 344 | 2016-10-01 | 2020-07-17 |
| Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs TOBI® PODHALER®, TOBI®, Bethkis® - Pseudomonas Aeruginosa in Cystic Fibrosis | Completed | Mylan Inc. | 409 | 2015-05-05 | 2022-03-22 | |
| Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) Tedizolid Phophate, Antibiotic comparator, Aztreonam - Skin Diseases, Infectious, Skin Diseases, Bacterial | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 120 | 2015-03-25 | 2019-08-07 |
| Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study Adherence dashboard motivational interviewing - Cystic Fibrosis | Completed | Landon Pediatric Foundation | 18 | 2015-03-01 | 2016-09-08 | |
| Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections. Ceftaroline fosamil, Vancomycin, Aztreonam - Complicated Skin and Soft Tissue Infection | Phase 3 | Terminated | Pfizer | 4 | 2014-06-01 | 2017-09-06 |
Showing 20 of 37. Sign in to see all of them.
Bacterial Infections (9) · Cystic Fibrosis (9) · Cellulitis (7) · Pseudomonas Infections (5) · Skin Diseases, Bacterial (5) · Infections (4) · Abscess (3) · Gram-Negative Bacterial Infections (3) · Soft Tissue Infections (3) · Wound Infection (3) · Bronchiectasis (2) · Enterobacteriaceae Infections (2) · Osteomyelitis (2) · Sepsis (2) · Skin Diseases, Infectious (2)
Gilead Sciences (7) · Pfizer (4) · Forest Laboratories (3) · Melinta Therapeutics, Inc. (2) · Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Jing Zhou (1) · Julio Ramirez (1) · Karl Landsteiner Insitute for Nephrology and Haemato-Oncology (1) · Landon Pediatric Foundation (1) · Liverpool Heart and Chest Hospital NHS Foundation Trust (1) · Loyola University (1) · Mylan Inc. (1)
United States (22) · Spain (10) · Germany (7) · Italy (7) · United Kingdom (7) · Argentina (6) · China (6) · Poland (6) · Austria (5) · Brazil (5) · Chile (5) · France (5) · Belgium (4) · Greece (4) · Israel (4)
Mark Bresnik, MD (3) · David Melnick, MSD (2) · Annelize Koch, MBChB (1) · Anthony J Schaeffer, MD (1) · Bruce K Rubin, MD (1) · Chris Landon, MD (1) · David Seligson, MD (1) · Diego Torres, MD (1) · Frans van den Berg, MD (1) · Freddy Frost, BMBS BMedSci (1) · George Retsch-Bogart, MD (1) · James Chalmers, MBChB, MRCP (1) · Jiasheng Zhang, Doctor (1)
PMID 30597021, PMID 30716446, PMID 34741280, PMID 34922058, PMID 20695801, PMID 21115456, PMID 27585969, PMID 28630189, PMID 30349845, PMID 15276398, PMID 15840453, PMID 19036671, PMID 19588358, PMID 21115454, PMID 21115455, PMID 22530208, PMID 22985692, PMID 24626872, PMID 25091537, PMID 27233377, PMID 28592230, PMID 28601833, PMID 29029278, PMID 29518178, PMID 30380060, PMID 31262767, PMID 32607967, PMID 33077658, PMID 33358119, PMID 33395210, PMID 37455237, PMID 38215770, PMID 38252170, PMID 4902833, PMID 8948280
2014 (1), 2015 (1), 2016 (1), 2018 (1), 2025 (1), 5UM1AI104681-09 (1)